GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Debt-to-Revenue

Bio-Techne (FRA:TE1) Debt-to-Revenue : 0.35 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio-Techne's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €12 Mil. Bio-Techne's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €347 Mil. Bio-Techne's annualized Revenue for the quarter that ended in Sep. 2024 was €1,043 Mil. Bio-Techne's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.34.


Bio-Techne Debt-to-Revenue Historical Data

The historical data trend for Bio-Techne's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Debt-to-Revenue Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.45 0.30 0.40 0.36

Bio-Techne Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.51 0.41 0.34 0.35

Competitive Comparison of Bio-Techne's Debt-to-Revenue

For the Biotechnology subindustry, Bio-Techne's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Debt-to-Revenue falls into.



Bio-Techne Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio-Techne's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.003 + 377.748) / 1076.767
=0.36

Bio-Techne's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.15 + 347.275) / 1043.208
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Bio-Techne Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines